Skip to main content

Table 4 Composite outcome representing treatment success after 18 months for each treatment group

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Second-line treatment N HbA1c reduction ≥ 0.5% (≥ 5.5 mmol/mol) Weight-loss ≥ 2 kg No treatment change over 18 months Overall success (i.e. attained all three endpoints)
MET + SU 847 559 (66.0) 217 (25.6) 478 (56.4) 81 (9.6)
MET + DPP-4i 608 335 (55.1) 260 (42.8) 300 (49.3) 104 (17.1)
MET + SGLT-2i 74 53 (71.6) 53 (71.6) 41 (55.4) 27 (36.5)
Other* 187 105 (56.2) 61 (32.6) 91 (48.7) 17 (9.1)
Overall 1716 1052 (61.3) 591 (34.4) 910 (53.0) 229 (13.3)
  1. Data are in n (%). Data from all patients who had both HbA1c and weight measurements available at baseline and at 18 months
  2. DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea
  3. *Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies